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There are many etiologies of peripheral precocious puberty (PPP) with diverse 
manifestations resulting from exposure to androgens, estrogens, or both.  The clinical 
presentation depends on the underlying process and may be acute or gradual.  The primary goals 
of therapy are to halt pubertal development and restore sex steroids to prepubertal values.  
Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height 
potential are additional considerations for many patients.  McCune-Albright syndrome (MAS) 
and Familial Male-Limited Precocious Puberty (FMPP) represent rare causes of PPP that arise 
from activating mutations in GNAS1 and the LH receptor gene, respectively.  Several different 
therapeutic approaches have been investigated for both conditions with variable success.  
Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in 
girls remains elusive.  In contrast, while the number of treated patients remains small, several 
successful therapeutic options for FMPP are available.   
Introduction 
Peripheral precocious puberty (PPP), or GnRH-independent precocious puberty, is 
defined as early pubertal maturation that is not a result of central activation of the hypothalamic-
pituitary-gonadal axis.  The etiology of PPP can be categorized into either genetic or acquired 
disorders and some vary by the gender of the child (Table 1).  Congenital or genetic causes 
include McCune-Albright syndrome (MAS), Familial Male-Limited Precocious Puberty (FMPP), 
and congenital adrenal hyperplasia (CAH).  Acquired causes include hormone-secreting tumors 
or cysts, exogenous hormone exposure, and the pseudo-precocious puberty seen in patients with 
profound primary hypothyroidism [1].  The treatment of PPP depends entirely on the underlying 
etiology.  This chapter will focus on the treatment of MAS and FMPP.   
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McCune-Albright Syndrome in Girls 
 MAS is a rare disorder characterized by the triad of polyostotic fibrous dysplasia, café-
au-lait macules, and precocious puberty.  The café-au-lait macules characteristic of MAS are 
classically described as having a “coast of Maine” or jagged border, in contrast to the smooth 
“coast of California” configuration seen in the café-au-lait spots in children with 
Neurofibromatosis.  Another unique feature of these lesions is that they usually follow the lines 
of Blaschko and do not cross the midline, although exceptions have been noted [2, 3].  The 
clinical manifestations of MAS are a result of constitutive activation of cells affected by a post-
zygotic gain of function mutation in the GNAS1 gene which encodes for the stimulatory subunit 
of the G-protein complex known as Gsα.  Individual phenotypes are exceedingly heterogeneous 
and depend on the number and types of tissues involved.  While precocious puberty is by far the 
most common endocrinopathy seen in MAS, many other forms of endocrine hyperfunction can 
occur, including hyperthyroidism, growth hormone excess, Cushing syndrome, and FGF23-
mediated hypophosphatemia.   
Precocious puberty in children with MAS is much more common in girls and results from 
estrogen secretion by autonomously functioning ovarian cysts [2].  Girls with MAS typically 
present with painless vaginal bleeding along with minimal breast enlargement, although breast 
tissue may have resolved by the time of referral.  Growth parameters and bone age x-ray are 
usually normal at the time of initial evaluation.  If MAS is suspected, initial work up should 
include both laboratory and radiographic studies.  Laboratory investigation typically reveals 
elevated estradiol with suppressed random and stimulated gonadotropins.  While a single 
suppressed LH may be sufficient in a patient with classic findings of MAS, a GnRH or GnRH 
analog stimulation test will provide more information about the HPG axis in equivocal situations.  
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Unilateral ovarian cysts are classically seen on pelvic ultrasound and may be mistaken for a 
neoplasm such as a Juvenile Granulosa Cell Tumor [4].  If the initial evaluation is consistent 
with MAS, a bone scan should be ordered to evaluate for fibrous dysplasia and screening for 
other endocrinopathies should be performed.  Almost all clinically significant foci of fibrous 
dysplasia are believed to be present by the age of 5 [2]. Therefore, the majority of skeletal 
lesions will be identified at the first evaluation since children with MAS usually come to medical 
attention between 3 to 10 years of age.  While genetic testing for a mutation in the GNAS gene is 
available, it is frequently of low yield in peripheral blood, especially in atypical cases [5].  The 
likelihood of detecting a mutation does, however, increase if an affected tissue is examined [6].  
As such, the diagnosis rests primarily on clinical criteria.  
The natural history of precocious puberty in girls with MAS is extremely variable and the 
frequency of vaginal bleeding is difficult to predict [2].  Girls with progressive disease and 
repeated exposure to estrogen will have growth acceleration and bone age advancement and may 
benefit from treatment.  However, treatment of PPP in girls with MAS is challenging and its 
benefits have not been well established due to the rarity of patients and the heterogeneous nature 
of the disease.  
A number of drugs have been investigated as potential pharmacologic approaches for the 
treatment of girls with MAS who have repeated episodes of vaginal bleeding (Table 2).  GnRH 
analogs as primary intervention have not been successful as gonadotropins are not elevated in 
these patients.  Cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) are two of 
the first agents historically used to treat precocious puberty, including in girls with MAS.  CPA 
is a steroidal antiandrogen that works predominantly at the androgen receptor, but also has 
progestin and antiestrogenic activity [7].  Likewise, MPA has local antiestrogen properties.   
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Despite initial positive short-term reports of efficacy in controlling breast development and 
vaginal bleeding, long-term treatment with these agents has proven unsatisfactory as they do not 
appear to influence growth rate or final adult height [7, 8].    
Ketoconazole has been successfully used in the short-term to treat PPP.  It works through 
inhibition of steroid biosynthesis by blockade of cytochrome P450 enzymes.  A report of 2 girls 
with MAS treated with ketoconazole over the course a year resulted in cessation of vaginal 
bleeding, reduction of estradiol levels, and decreased bone age advancement without any acute 
adverse events [9].  However, concerns regarding safety, including risk of adrenal insufficiency 
and hepatotoxicity, and lack of long-term effectiveness have limited its use.  Ketoconazole has 
been associated with reversible liver toxicity in 1/100,000 cases and requires close monitoring of 
liver function [9].    
 Aromatase inhibitors, which were originally developed for the treatment of estrogen 
receptor-positive breast cancer, are relatively newer agents that have been used in the treatment 
of PPP in girls with MAS.  Aromatase catalyzes the rate-limiting step in the conversion of 
testosterone to estradiol and androstendione to estrone [10].  This class of drugs binds to the 
cytochrome P450 portion of aromatase, thus inhibiting the conversion of androgens to estrogens 
[10].  Aromatase inhibitors can be classified by type (steroidal or nonsteroidal) and generation 
(first, second, or third) and vary with regards to potency of estrogen suppression.   
 Testolactone, a first generation aromatase inhibitor, was found to have minimal success 
in the treatment of girls with MAS.  One study that followed 7 girls with MAS treated for at least 
3 years showed a reduction in serum estradiol levels and frequency of vaginal bleeding.  
However,  mean predicted adult height (PAH) was not significantly improved after treatment 
[11].  The positive effects seen in this study were most marked in the first year after therapy, 
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which is consistent with an escape effect of the drug.  Another disadvantage is that this 
medication needs to be dosed four times daily, making compliance difficult.  As such, this 
medication is not routinely used.     
  A second generation aromatase inhibitor, fadrozole, has likewise been found to be 
ineffective in the treatment of precocious puberty in girls with MAS.  It also carries with it the 
concern for adrenal suppression.  One study followed 16 girls with MAS treated with fadrozole 
and found that it did not result in a significant decrease in mean estradiol or mean ovarian 
volumes compared to pre-treatment values [12].  A decrease in frequency of vaginal bleeding 
was seen initially, but did not persist.  Mean growth rate SDS was not significantly different 
prior to therapy and PAH was not significantly improved.  A dose-dependent inhibition of 
adrenal steroid biosynthesis was also observed, and 3 girls ultimately required hydrocortisone 
replacement therapy.  It appears that fadrozole is not sufficiently potent to block estrogen 
synthesis in the majority of girls with MAS and carries with it the concern for adrenal 
insufficiency.   
 Two third generation aromatase inhibitors, anastrozole and letrozole, have been trialed 
for the treatment of precocious puberty in girls with MAS.  Despite early reports of efficacy, an 
international, multi-institutional trial investigating the utility of anastrozole found it to be 
ineffective [13].  This study followed 28 girls with MAS for 1 year and found no difference in 
frequency of vaginal bleeding or bone age advancement when compared to pretreatment values.  
Mean ovarian and uterine volumes were likewise unaffected.  Growth velocity z-scores 
decreased from 1.40 ± 3.15 at study entry to 0.26 ± 2.71 during treatment, however this was not 
statistically significant.  There were no significant adverse events reported, so while it appears to 
be safe, anastrozole is not recommended for treatment of precocious puberty in girls with MAS. 
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 Letrozole, on the other hand, has demonstrated some short-term success in the treatment 
of girls with MAS.  One study followed 9 girls treated with letrozole for up to 36 months and 
noted a significant decrease in growth velocity SDS and bone age to chronological age ratio 
(BA/CA) [14].  Of the 9 girls treated, 6 ceased having vaginal bleeding and 3 had a reduction in 
frequency of vaginal bleeding.  Mean serum estradiol and ovarian volumes fell at 6 months but 
increased back to baseline by 12 and 24 months.  The drug was tolerated well overall, although 
one girl developed a large ovarian cyst with torsion that required surgical intervention.  Although 
this event may or may not have been related to the letrozole, further investigation is needed into 
the long-term safety and efficacy of this drug.  
  Another class of drugs that has been used with some success in girls with MAS is 
estrogen receptor modulators such as tamoxifen and fulvestrant.  These drugs were also first 
designed for use in the treatment of breast cancer.  Tamoxifen, a selective estrogen receptor 
modulator, was found to have positive results in a year-long multicenter trial of 25 girls with 
MAS and PPP [15].  After an observation period of 6 months, girls were started on tamoxifen at 
a dose of 20 mg once daily.  Episodes of vaginal bleeding decreased from 3.42 ± 3.36 per year to 
1.17 ± 1.41 per year.  Growth velocity and bone maturation also significantly decreased.  While 
there were no significant adverse events reported, uterine volumes were unexpectedly found to 
increase throughout the study.  This raised safety concerns given the association of tamoxifen 
and stromal tumors.  As such, periodic pelvic ultrasound examination in girls treated with 
tamoxifen is recommended.  Long-term studies using tamoxifen in MAS have yet to be 
published in children.  
  Fulvestrant, a pure estrogen receptor blocker that is given intramuscularly, was recently 
found to be moderately effective in treating precocious puberty in girls with MAS in a 
Peripheral Precocious Puberty 
7 
 
multicenter, international study [16].  In this trial, 30 girls were treated for 1 year at a goal dose 
of 4 mg/kg IM monthly.  Median vaginal bleeding days significantly decreased from 12 
days/year to 1 day/year and rates of bone age advancement (ΔBA/ΔCA) significantly decreased 
from 1.99 to 1.06.  Mean growth velocity and predicted adult height remained equivalent and 
uterine volumes were stable.  The most common adverse event was injection site reactions.  It is 
speculated that longer treatment might improve the other growth parameters given that there was 
a progressive decrease in bone age advancement in the treated girls.  However this has not yet 
been reported in the literature.   
 Lastly, surgical options including cystectomy or oophorectomy have been used in girls 
with MAS.  This approach is considered sub-optimal as there is a high likelihood of cyst 
recurrence.  These surgeries may also impact fertility in women with the potential for otherwise 
normal reproductive function and thus are not recommended.  As in other forms of PPP, the 
development of secondary CPP can occur and responds to standard GnRH analog therapy.   
 Several challenges are faced when investigating treatment of precocious puberty in girls 
with MAS.  The scarcity of affected patients necessitates multi-center studies which require 
considerable resources and a collaborative approach.  Given the extreme variability between 
patients, girls typically serve as their own controls.  It is impossible to know, however, whether 
periods of apparent disease quiescence are due to the intervention or simply reflect the natural 
history of the condition.  Lastly, concurrent endocrinopathies such as subclinical 
hyperthyroidism and/or growth hormone excess along with bony deformities render it difficult to 
derive accurate information regarding the relationship between linear growth rates and degree of 
skeletal maturation and precocious puberty in girls with MAS. 
McCune-Albright Syndrome in Boys 
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 MAS in boys is exceptionally rare.  PPP in boys with MAS occurs less frequently and 
later in life when compared to girls [17].  When it occurs, it is typically associated with penile 
growth and bilateral testicular enlargement secondary to Leydig cell hyperplasia.  Labs in boys 
with MAS reveal elevated testosterone with suppressed gonadotropins.  Even in the absence of 
precocious puberty, testicular pathology can be seen in boys with MAS, most commonly 
unilateral or bilateral macroorchidism [2].  One study evaluated 54 males with MAS and found 
that 44% had macroorchidism, including 13 of 26 children [18].  Only 21% presented with 
precocious puberty, which is in contrast to the high numbers of girls with MAS who initially 
present with signs of precocious puberty.  However, 81% of the males had abnormalities on 
testicular ultrasound, the most common of which were hyperechoic or hypoechoic lesions.  Other 
ultrasound findings included microlithiasis, heterogeneity, and focal calcifications.  Conservative 
management of testicular lesions with observation and serial imaging is recommended as cancer 
is rare.  This study showed that contrary to conventional thinking, MAS-associated gonadal 
involvement is not significantly more common in females than males when testicular ultrasounds 
are performed.  
 The treatment of PPP in boys with MAS has not been extensively studied in the literature 
due to the rarity of patients.  Combination therapy with an androgen receptor blocker and an 
aromatase inhibitor is typically used [2].  The drugs used to treat FMPP, which will be discussed 
in the next section, should theoretically work in this patient population as well.  A single report 
noted normalization of growth velocity, regression of genital changes, and stabilization of 
testicular volume in a 4.6 year old boy with PPP and MAS treated with bicalutamide and 
anastrazole [19].  This was the first reported use of bicalutamide, a nonsteroidal antiandrogen, in 
a boy with MAS.   
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Familial Male-Limited Precocious Puberty 
 FMPP, or testotoxicosis, is a rare genetic disorder caused by a mutation in the gene 
encoding the LH receptor that results in constitutive activation.  The mutation can occur de novo 
or it can be inherited in an autosomal dominant fashion.  The phenotype is limited to males.  
Boys present with early pubertal development, typically before the age of 4, with rapid growth, 
tall stature, an enlarged penis, minimal testicular enlargement, and pubic hair [20].  Labs reveal 
elevated testosterone with suppressed gonadotropins.  If left untreated a short adult height will 
result due to early closure of the epiphyses.  Given the rarity of FMPP, extensive treatment data 
in this disorder is lacking.  Drugs that have been used to date are listed in Table 3.     
    As in MAS, CPA and MPA have been used in boys with FMPP for their antiandrogen 
properties.  A Brazilian study reported limited success in 5 boys with FMPP treated with CPA at 
a dose of 70 mg/m2 for a mean period of 5 years [21].  One patient also received MPA in 
combination therapy and two patients were ultimately started on an aromatase inhibitor as well.  
Compared to pretreatment values, growth velocity decreased significantly during treatment.  The 
BA/CA ratio likewise significantly decreased.  Despite these improvements, there was limited 
efficacy with regards to normal adult height attainment.  The same study also evaluated 5 boys 
treated with ketoconazole at a dose of 10 mg/kg for a mean duration of 8 years.  The results were 
nearly identical to the CPA-treated group, except the boys on ketoconazole had significantly 
lower testosterone levels compared to the group treated with CPA.   
Ketoconazole has been effective in the treatment of boys with FMPP due to its ability to 
inhibit adrenal and testicular androgen biosynthesis, although there are a number of safety 
concerns.  The primary safety concerns are hepatotoxicity and adrenal suppression.  Mild 
adverse effects include gynecomastia, nausea, and diarrhea.  Ketoconazole is metabolized in the 
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liver and reports ranging from mild transaminitis to severe liver damage have been described.  
The prevalence of mild, asymptomatic, reversible elevation in the transaminases in adults 
receiving an average of 200 mg daily ranges from 5-17%, with hepatitis developing in 2.9% [22].  
In children with FMPP, there has been one reported case of severe liver damage in a child 
receiving high dose therapy (1,200 mg/day) with reversal of the liver disease after dose reduction 
[23].   
Ketoconazole can be used as a solo agent or used in combination with other drugs such as 
aromatase inhibitors.  It is typically dosed three times daily in the range of 10-20 mg/kg/day.  A 
study using it alone found that it was well-tolerated and effective in suppressing pubertal 
symptoms and increasing adult height [22].  This French study followed 5 boys with FMPP who 
were treated with ketoconazole for 5-10 years until adult height was reached.  The median dose 
during the course of therapy was 16.2 mg/kg/day.  Safety was monitored through routine testing 
of liver enzymes, cortisol, and ACTH.  Growth velocity decreased significantly with 
improvement in the BA/CA ratio.  Testosterone levels significantly decreased and remained low 
during treatment.  PAH significantly increased and final median adult height was -0.3 SDS (-1.7 
to +1.1 SDS).  One patient experienced a mild transaminitis that self-resolved.  Another patient 
was found to have an elevated ACTH level to 347 pg/mL with a normal cortisol, and required 
hydrocortisone treatment during stress for a period of 6 months until it normalized.  Despite this 
complication, the authors concluded that ketoconazole should be a first line therapy in boys with 
FMPP due to their favorable results. 
 Another successful therapeutic regimen in boys with FMPP is the combination of 
spironolactone, an antiandrogen that works at the receptor, along with testolactone, an aromatase 
inhibitor.  Aromatase inhibitors are used in combination therapies in FMPP due to the critical 
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role that estrogen plays in epiphyseal fusion.  One study followed 10 boys with FMPP treated 
with spironolactone twice daily and testolactone 3-4 times daily for six years [24].  A GnRH 
analog was also added as necessary for central precocious puberty (CPP).  Growth velocity 
decreased significantly after 1 year of treatment and was maintained during the next 5 years.  
PAH increased progressively after the first year of treatment from 106.7 ± 14.7 cm at baseline to 
173.6 ± 10.1 cm after 6 years.  There were no significant adverse effects.  The subjects were not 
followed until adult height attainment, but these results led the authors to conclude that this 
combination of therapy was successful in normalizing growth.  A major downside of this 
approach, however, is the need for multiple daily doses of medication that may limit compliance.  
 Finally, recent reports have shown modest success using the combination of bicalutamide 
and a third-generation aromatase inhibitor in boys with FMPP.  Bicalutamide is a potent 
nonsteroidal antiandrogen that binds to and inhibits the androgen receptor and increases the 
receptor’s degradation [25].  This drug was initially developed for the treatment of prostate 
cancer.  Conveniently, it can be dosed once daily at a dose of 2 mg/kg, though it is fairly 
expensive.  The most common adverse effects are gynecomastia and breast pain [25].  The 
BATT study (Bicalutamide and Anastrozole Treatment of Testotoxicosis), a multicenter, 
international trial of 13 boys with FMPP treated with bicalutamide and anastrozole for 12 months 
found decreased growth rates from baseline in 9 of the 13 patients, however this was not 
statistically significant [26]. In contrast, the BA/CA ratio decreased significantly from 2.1 ± 0.6 
to 1.0 ± 0.4.  Pubic hair and Tanner stage remained largely unchanged and mean testicular 
volume minimally increased.  Almost half of the patients experienced gynecomastia and 12.5% 
reported breast tenderness.  The extension phase of this study following the children until adult 
height has not yet been published, however promising results were seen a small case series of 2 
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boys treated with the same regimen who were followed for almost 5 years.  In this study, bone 
age advancement stabilized and PAH increased [25].    
Lastly, FMPP is often complicated by the activation of the hypothalamic-pituitary-
gonadal axis, or CPP, and GnRH analogs are frequently necessary as adjuvant therapy.  
Although it has not been rigorously studied, usual clinical care includes monitoring boys with 
FMPP for secondary CPP and initiating treatment once central puberty commences for optimal 
adult height outcome.   
Conclusion 
 There are a number of causes of PPP in children and treatment depends on the etiology.  
There is a lack of sufficient treatment data in children with genetic causes of PPP due to the 
rarity of patients with MAS and FMPP.  Despite trials of a number of therapies in MAS, 
treatment remains challenging and a gold-standard therapeutic regimen does not yet exist.  
However, a number of successful treatment options are available for boys with FMPP.  Further 
prospective studies involving more patients will hopefully illuminate optimal therapeutic 
strategies for the treatment of children with both of these rare forms of precocious puberty.   
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Table 1. Differential Diagnosis of Peripheral Precocious Puberty 
Girls Boys 
Ovarian tumor Familial Male-Limited Precocious Puberty 
Ovarian cyst Leydig cell tumor 
Aromatase excess HCG-secreting tumor 




Exogenous sex steroid exposure 
Primary hypothyroidism 
Congenital adrenal hyperplasia 
Peutz-Jeghers Syndrome 
























Table 2. Treatment Options for MAS 
Drug Name Mechanism of Action 
Ketoconazole Inhibits P450 enzymes 
Medroxyprogesterone Antiandrogen 
Cyproterone acetate Antiandrogen 
Testolactone First-generation AI 
Fadrozole Second-generation AI 
Anastrozole Third-generation AI 
Letrozole Third-generation AI 
Tamoxifen Selective Estrogen Receptor blocker 

























Table 3. Treatment Options for FMPP 
Drug Name Mechanism of Action 
Cyproterone acetate Antiandrogen 
Medroxyprogesterone acetate Antiandrogen 
Ketoconazole Inhibits P450 enzymes 
Spironolactone Weak antiandrogen agent 
Testolactone First-generation AI 
Anastrozole Third-generation AI 
Letrozole Third-generation AI 
Bicalutamide Potent nonsteroidal antiandrogen agent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
